title: Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials.
abstract: The Cholesterol Lowering Atherosclerosis Study, a randomized angiographic clinical trial, demonstrated the beneficial effect of niacin/colestipol plus diet therapy on coronary atherosclerosis. Outcome was determined by panel-based estimates (viewed in both still and cine modes) of percent stenosis severity and change in native artery and bypass graft lesions. Computer-based quantitative coronary angiography (QCA) was also used to measure lesion and bypass graft stenosis severity and change in individual frames closely matched in orientation, opacification, and cardiac phase. Both methods jointly evaluated 350 nonoccluded lesions. The correlation between QCA and panel estimates of lesion size was 0.70 (p less than 0.0001) and for change in lesion size was 0.28 (p = 0.002). Agreement between the two methods in classifying lesion changes (i.e., regression, unchanged, or progression) occurred for 60% (210 of 350) of the lesions kappa +/- SEM = 0.20 +/- 0.05, p less than 0.001). The panel identified 442 nonoccluded lesions for which QCA stenosis measurements could not be obtained. Lesions not measurable by QCA included those with stenosis greater than 85% that could not be reliably edge tracked, segments with diffuse or ecstatic disease that had no reliable reference diameter, and segments for which matched frames could not be located. Seventy-nine lesions, the majority between 21% and 40% stenosis, were identified and measured by QCA but were not identified by the panel. This comparison study demonstrates the need to consider available angiographic measurement methods in relation to the goals of their use.
authors.affiliation: Department of Preventive Medicine, University of Southern California, Los Angeles.
authors.forename: W J
authors.initials: WJ
authors.lastname: Mack
authors.forename: R H
authors.initials: RH
authors.lastname: Selzer
authors.forename: J M
authors.initials: JM
authors.lastname: Pogoda
authors.forename: P L
authors.initials: PL
authors.lastname: Lee
authors.forename: A M
authors.initials: AM
authors.lastname: Shircore
authors.forename: S P
authors.initials: SP
authors.lastname: Azen
authors.forename: D H
authors.initials: DH
authors.lastname: Blankenhorn
mesh_terms: D000328:Adult; D003084:Colestipol / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003201:Computers; D017023:Coronary Angiography / Q000379:methods*; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging* / Q000178:diet therapy / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000627:therapeutic use
chemical_list: D009525:Niacin; D003084:Colestipol